Senate Finance Committee Chairman Orrin Hatch (R-UT) on May 11 said the White House remains unwilling to move beyond five years of market exclusivity for biologics in the Trans Pacific Partnership rather than the 12 years he is seeking, and warned that the administration's failure to change on the issue would essentially kill chances for a Senate vote on the agreement. "We had multiple meetings with the White House and they don't seem to be willing to go beyond the five years [of market exclusivity] and frankly I think we got to have at least 12 years or the system does not work," he said. Anything short of that will mean the U.S. will get "screwed," or be "very badly mistreated by countries which will be basically stealing our patents," he said.
展开▼
